Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-Label, Dose Escalation Trial Of REDD14NP Delivered By A Single Intravitreal Injection To Patients With Choroidal Neovascularization (CNV) Secondary To Exudative Age-Related Macular Degeneration ("Wet AMD").

NCT00725686 is registered in ClinicalTrials.gov with Quark Pharmaceuticals as lead sponsor.

NCT NCT00725686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00725686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-Label, Dose Escalation Trial Of REDD14NP Delivered By A Single Intravitreal Injection To Patients With Choroidal Neovascularization (CNV) Secondary To Exudative Age-Related Macular Degeneration ("Wet AMD").
Lead sponsor
Quark Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2007
Completion date
November 30, 2010
Enrollment
54 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration